cetirizine has been researched along with Asthma, Bronchial in 77 studies
Cetirizine: A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.
cetirizine : A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the efficacy and safety of a fixed-dose combination of montelukast and levocetirizine in patients with perennial allergic rhinitis with mild to moderate asthma compared with the efficacy and safety of montelukast alone." | 9.27 | A Randomized, Multicenter, Double-blind, Phase III Study to Evaluate the Efficacy on Allergic Rhinitis and Safety of a Combination Therapy of Montelukast and Levocetirizine in Patients With Asthma and Allergic Rhinitis. ( Chang, YS; Cho, YJ; Cho, YS; Choi, BW; Chung, JH; Jee, YK; Jo, EJ; Jung, J; Kim, HK; Kim, MK; Kim, SH; Lee, BJ; Lee, JM; Lee, SK; Lee, SY; Park, CS; Park, HS; Park, HW; Park, JW; Yoo, KH; Yoon, HJ, 2018) |
| "Treatment with cetirizine-D twice daily significantly reduced rhinitis and asthma symptoms and improved overall asthma quality of life in patients with seasonal AR and concomitant mild-to-moderate asthma." | 9.12 | Comparison of cetirizine-pseudoephedrine and placebo in patients with seasonal allergic rhinitis and concomitant mild-to-moderate asthma: randomized, double-blind study. ( Chapman, D; de Guia, EC; Finn, AF; Hewlett, D; Kramer, B; LaForce, C; Nathan, RA; Ratner, P, 2006) |
| "Fifteen atopic asthmatics were randomized in double-blind, cross-over fashion to receive for 1 week either levocetirizine 5 mg or placebo." | 9.11 | Single and short-term dosing effects of levocetirizine on adenosine monophosphate bronchoprovocation in atopic asthma. ( Gray, RD; Lee, DK; Lipworth, BJ; Robb, FM; Soutar, PC; Wilson, AM, 2004) |
| "We sought to establish whether the use of cetirizine compared with placebo for 18 months in infants with atopic dermatitis suppressed or truly delayed the onset of asthma, even after cessation of therapy." | 9.09 | A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow-up. ( Warner, JO, 2001) |
| "Cetirizine, a highly specific H1 receptor antagonist with modest sedation and anticholinergic effects at the higher doses required for bronchodilation, may be useful for treating concomitant allergy and symptoms of asthma." | 9.08 | Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma. ( Aaronson, DW, 1996) |
| "Many potential users of the H1 antihistamine cetirizine are asthmatic and may be using inhaled albuterol." | 9.08 | Comparison of the bronchodilatory effects of cetirizine, albuterol, and both together versus placebo in patients with mild-to-moderate asthma. ( Corren, J; Katz, RM; Nicodemus, CF; Rachelefsky, GS; Schanker, HM; Siegel, SC; Spector, SL, 1995) |
| "This study explored the safety and efficacy of cetirizine for treatment of allergic rhinitis and asthma." | 9.08 | Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. ( Findlay, SR; Glovsky, MM; Grant, JA; Grossman, J; Kaiser, H; Meltzer, EO; Mitchell, DQ; Nicodemus, CF; Pearlman, D; Selner, J, 1995) |
| "The objective of this study was to investigate the possible anti-asthma role of Cetirizine." | 9.08 | [Cetirizine improves the resistance of airway and pulmonary function in patients with asthma]. ( He, T; Luo, Y; Wang, Z; Yuan, Y; Zeng, J, 1996) |
| "Eighteen days of treatment with cetirizine did not significantly reduce the intensity of the early and late asthmatic responses." | 9.07 | Lack of effect of cetirizine on early and late asthmatic response after allergen challenge. ( de Bruin-Weller, MS; de Monchy, JG; Rijssenbeek-Nouwens, LH, 1994) |
| "Cetirizine is a highly sensitive H1 antihistamine with particular antiallergic properties, which has been shown to be effective in the treatment of allergic rhinitis, urticaria, and hay-fever-associated asthma." | 9.07 | Effect of cetirizine, a new H1 antihistamine, on the early and late allergic reactions in a bronchial provocation test with allergen. ( Leuenberger, P; Pécoud, A; Wasserfallen, JB, 1993) |
| " The effect of both a single dose (15 mg) and 7 days of treatment (15 mg twice daily) with cetirizine, a potent H1 antagonist on bronchoconstriction induced by histamine and leukotriene D4 (LTD4) has been examined in 10 patients with mild atopic asthma in a placebo-controlled, double-blind, crossover study." | 9.07 | Effect of cetirizine on histamine- and leukotriene D4-induced bronchoconstriction in patients with atopic asthma. ( De Vos, C; Ghosh, SK; McIlroy, I; Patel, KR, 1991) |
| " To evaluate this oral drug's efficacy in treating asthma, we examined the bronchodilator effects of 5-, 10-, and 20-mg doses as well as the protective effects of these doses against histamine-provoked bronchospasm." | 9.06 | Cetirizine inhibition of histamine-induced bronchospasm. ( Brik, A; Gong, H; Tashkin, DP, 1987) |
| " We investigated the effect of 2 weeks therapy with oral cetirizine (10 mg twice daily) on methacholine bronchial reactivity in 14 asthmatics." | 9.06 | The effect of 2 weeks treatment with cetirizine on bronchial reactivity to methacholine in asthma. ( Finnerty, JP; Holgate, ST; Rihoux, JP, 1990) |
| "In a double-blind study, 29 patients suffering from pollen asthma were administered placebo for 14 days and were compared with 28 patients administered cetirizine, a new drug displaying a potent and selective H1 antagonism and inhibiting effect on infiltrating cells." | 9.06 | Protective effect of cetirizine in patients suffering from pollen asthma. ( Arendt, C; Bruttmann, G; Pedrali, P; Rihoux, JP, 1990) |
| "The protective efficacy of oral cetirizine, a selective and potent H1-receptor antagonist, against the immediate bronchoconstrictive response to allergen inhalation and exercise challenge was evaluated in 16 subjects with stable, predominantly mild asthma." | 9.06 | Effects of oral cetirizine, a selective H1 antagonist, on allergen- and exercise-induced bronchoconstriction in subjects with asthma. ( Dauphinee, B; Djahed, B; Gong, H; Tashkin, DP; Wu, TC, 1990) |
| "Antihistamines were investigated for use in asthma shortly after discovery over fifty years ago." | 8.79 | Antihistamines in the treatment of asthma. ( Grant, JA; Malick, A, 1997) |
| "Because the older antihistamines possessed relatively weak antihistaminic action, as well as sedative and anticholinergic effects, they could not be administered in doses high enough to confer relief to atopic patients with asthma." | 8.78 | Antihistamines in the treatment of clinical asthma. ( Rafferty, P, 1990) |
| "Objective To investigate the effects of cetirizine on Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway and mast cell activation in asthmatic mice by establishing a mouse model of asthma." | 8.12 | [Cetirizine inhibits activation of JAK2-STAT3 pathway and mast cell activation in lung tissue of asthmatic mice]. ( Huang, B; Lei, L; Luo, S; Qu, T, 2022) |
| "In cats with experimentally induced asthma, cyproheptadine and cetirizine were not effective in decreasing airway eosinophilic inflammation or in altering several other measured immunologic variables." | 7.74 | Effects of cyproheptadine and cetirizine on eosinophilic airway inflammation in cats with experimentally induced asthma. ( Jiji, RD; McGee Turner, JB; Reinero, CR; Schooley, EK; Spinka, CM, 2007) |
| "Cetirizine was given once a day at the dosage of 10 mg for four weeks." | 6.69 | [The efficacy of cetirizine in the treatment of mild allergic asthma due to grasses]. ( Biasi, D; Carletto, A; Corrocher, R; Pacor, ML, 1998) |
| "Cetirizine has several antiallergic properties that suggest a potential effect on the development of airway inflammation and asthma in infants with atopic dermatitis." | 6.69 | Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised, placebo-controlled trial: first results of ETAC. Early Treatment of the Atopic Child. ( , 1998) |
| "Cetirizine is an antiallergic drug that can reduce both inflammatory infiltrate and ICAM-I expression induced by allergen-specific conjunctival challenge." | 6.68 | Cetirizine reduces ICAM-I on epithelial cells during nasal minimal persistent inflammation in asymptomatic children with mite-allergic asthma. ( Canonica, GW; Ciprandi, G; Cozzani, S; Fasce, L; Grimaldi, I; Pronzato, C; Tosca, MA, 1996) |
| "Cetirizine is a non-sedating H1 antihistamine which is effective in the treatment of allergic rhinitis and urticaria." | 6.68 | A comparison of the effects of oral cetirizine and inhaled beclomethasone on early and late asthmatic responses to allergen and the associated increase in airways hyperresponsiveness. ( Bentley, AM; De Vos, C; Durham, SR; Hanotte, F; Walker, S, 1996) |
| "Cetirizine is a selective H1 antagonist that inhibits the eosinophil recruitment induced by allergen in the skin." | 6.67 | Inhibitory effect of cetirizine on the bronchial eosinophil recruitment induced by allergen inhalation challenge in allergic patients with asthma. ( Chanez, P; Clauzel, AM; De Vos, C; Godard, P; Michel, FB; Rédier, H; Rifaï, N, 1992) |
| " Results demonstrate improved activity of antihistamines by 2 phytochemicals, suggesting dosing strategies for animal trials of ASX- or GB-augmented formulations for seasonal allergic rhinitis and asthma." | 5.38 | In vitro suppression of lymphocyte activation in patients with seasonal allergic rhinitis and pollen-related asthma by cetirizine or azelastine in combination with ginkgolide B or astaxanthin. ( Abal, A; Al-Awadhi, R; Al-Sharah, S; Arifhodzic, N; Azeamouzi, C; Haines, D; Mahmoud, FF; Tosaki, A, 2012) |
| "Antihistamines have been shown to have bronchodilatory effects, effects on allergen-, exercise-, and adenosine-monophosphate-challenge testing, and also to prevent allergen-induced nonspecific airways hyperresponsiveness." | 5.33 | The role of antihistamines in asthma management. ( Wilson, AM, 2006) |
| "The aim of this study was to evaluate the efficacy and safety of a fixed-dose combination of montelukast and levocetirizine in patients with perennial allergic rhinitis with mild to moderate asthma compared with the efficacy and safety of montelukast alone." | 5.27 | A Randomized, Multicenter, Double-blind, Phase III Study to Evaluate the Efficacy on Allergic Rhinitis and Safety of a Combination Therapy of Montelukast and Levocetirizine in Patients With Asthma and Allergic Rhinitis. ( Chang, YS; Cho, YJ; Cho, YS; Choi, BW; Chung, JH; Jee, YK; Jo, EJ; Jung, J; Kim, HK; Kim, MK; Kim, SH; Lee, BJ; Lee, JM; Lee, SK; Lee, SY; Park, CS; Park, HS; Park, HW; Park, JW; Yoo, KH; Yoon, HJ, 2018) |
| "We sought to investigate the efficacy of the DP1 antagonist laropiprant (alone or with montelukast) in asthma and seasonal AR and explore whether sequence variations in PTGDR are associated with asthma severity." | 5.14 | Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis. ( Dass, SB; Lai, E; Liu, N; Loeys, T; Philip, G; Reiss, TF; van Adelsberg, J; Wong, P, 2009) |
| "Subjects with asthma and perennial allergic rhinitis entered a randomized double blind crossover study comparing montelukast 10 mg and cetirizine 10 mg to extra-fine inhaled beclomethasone 400 mcg/day and intranasal beclomethasone 200 mcg/day, each taken once daily for 2 months, after 2-week placebo washouts." | 5.12 | Combined mediator blockade or topical steroid for treating the unified allergic airway. ( Barnes, ML; Burns, P; Fardon, TC; Lipworth, BJ; Menzies, D; Wilson, AM, 2007) |
| "Treatment with cetirizine-D twice daily significantly reduced rhinitis and asthma symptoms and improved overall asthma quality of life in patients with seasonal AR and concomitant mild-to-moderate asthma." | 5.12 | Comparison of cetirizine-pseudoephedrine and placebo in patients with seasonal allergic rhinitis and concomitant mild-to-moderate asthma: randomized, double-blind study. ( Chapman, D; de Guia, EC; Finn, AF; Hewlett, D; Kramer, B; LaForce, C; Nathan, RA; Ratner, P, 2006) |
| "Fifteen atopic asthmatics were randomized in double-blind, cross-over fashion to receive for 1 week either levocetirizine 5 mg or placebo." | 5.11 | Single and short-term dosing effects of levocetirizine on adenosine monophosphate bronchoprovocation in atopic asthma. ( Gray, RD; Lee, DK; Lipworth, BJ; Robb, FM; Soutar, PC; Wilson, AM, 2004) |
| "Sixteen atopic patients with mild-to-moderate asthma of whom 10 were receiving inhaled corticosteroid therapy (all had positive results to house dust mite on skin prick testing) were randomized in a double-blind, placebo-controlled, cross-over fashion to receive single doses of 5 mg of desloratadine, 180 mg of fexofenadine hydrochloride (FEX), 5 mg of levocetirizine dihydrochloride (LEV), or placebo, with AMP challenge performed 12 hours after dosing." | 5.10 | Comparative in vivo bioactivity of modern H1-antihistamines on AMP challenge in atopic asthma. ( Bates, CE; Currie, GP; Lee, DK; Lipworth, BJ, 2003) |
| "We sought to establish whether the use of cetirizine compared with placebo for 18 months in infants with atopic dermatitis suppressed or truly delayed the onset of asthma, even after cessation of therapy." | 5.09 | A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow-up. ( Warner, JO, 2001) |
| "To compare the antiasthmatic efficacy of inflammatory mediator blockade versus topical corticosteroid therapy in patients with seasonal allergic rhinitis (SAR) and asthma, 14 patients were enrolled into a single-blind, double-dummy, placebo-controlled crossover study comparing 2 wk therapy of (1) 400 microgram orally inhaled budesonide plus 200 microgram intranasal budesonide (BUD) or (2) 10 mg oral montelukast plus 10 mg oral cetirizine (ML + CZ)." | 5.09 | Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma. ( Dempsey, OJ; Lipworth, BJ; Orr, LC; Sims, EJ; Wilson, AM, 2000) |
| "Twenty-one patients with seasonal allergic rhinitis and asthma were enrolled into a single-blind, placebo-controlled, crossover study comparing 2 weeks of 1) 400 microg inhaled plus 200 microg intranasal budesonide once daily and 2) 10 mg montelukast plus 10 mg cetirizine once daily." | 5.09 | Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. ( Coutie, WJ; Gardiner, Q; Lipworth, BJ; Orr, LC; Sims, EJ; White, PS; Wilson, AM, 2001) |
| "This study explored the safety and efficacy of cetirizine for treatment of allergic rhinitis and asthma." | 5.08 | Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. ( Findlay, SR; Glovsky, MM; Grant, JA; Grossman, J; Kaiser, H; Meltzer, EO; Mitchell, DQ; Nicodemus, CF; Pearlman, D; Selner, J, 1995) |
| "Cetirizine, a highly specific H1 receptor antagonist with modest sedation and anticholinergic effects at the higher doses required for bronchodilation, may be useful for treating concomitant allergy and symptoms of asthma." | 5.08 | Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma. ( Aaronson, DW, 1996) |
| "The objective of this study was to investigate the possible anti-asthma role of Cetirizine." | 5.08 | [Cetirizine improves the resistance of airway and pulmonary function in patients with asthma]. ( He, T; Luo, Y; Wang, Z; Yuan, Y; Zeng, J, 1996) |
| "Many potential users of the H1 antihistamine cetirizine are asthmatic and may be using inhaled albuterol." | 5.08 | Comparison of the bronchodilatory effects of cetirizine, albuterol, and both together versus placebo in patients with mild-to-moderate asthma. ( Corren, J; Katz, RM; Nicodemus, CF; Rachelefsky, GS; Schanker, HM; Siegel, SC; Spector, SL, 1995) |
| "Eighteen days of treatment with cetirizine did not significantly reduce the intensity of the early and late asthmatic responses." | 5.07 | Lack of effect of cetirizine on early and late asthmatic response after allergen challenge. ( de Bruin-Weller, MS; de Monchy, JG; Rijssenbeek-Nouwens, LH, 1994) |
| "Cetirizine is a highly sensitive H1 antihistamine with particular antiallergic properties, which has been shown to be effective in the treatment of allergic rhinitis, urticaria, and hay-fever-associated asthma." | 5.07 | Effect of cetirizine, a new H1 antihistamine, on the early and late allergic reactions in a bronchial provocation test with allergen. ( Leuenberger, P; Pécoud, A; Wasserfallen, JB, 1993) |
| " The effect of both a single dose (15 mg) and 7 days of treatment (15 mg twice daily) with cetirizine, a potent H1 antagonist on bronchoconstriction induced by histamine and leukotriene D4 (LTD4) has been examined in 10 patients with mild atopic asthma in a placebo-controlled, double-blind, crossover study." | 5.07 | Effect of cetirizine on histamine- and leukotriene D4-induced bronchoconstriction in patients with atopic asthma. ( De Vos, C; Ghosh, SK; McIlroy, I; Patel, KR, 1991) |
| " We investigated the effect of 2 weeks therapy with oral cetirizine (10 mg twice daily) on methacholine bronchial reactivity in 14 asthmatics." | 5.06 | The effect of 2 weeks treatment with cetirizine on bronchial reactivity to methacholine in asthma. ( Finnerty, JP; Holgate, ST; Rihoux, JP, 1990) |
| "In a double-blind study, 29 patients suffering from pollen asthma were administered placebo for 14 days and were compared with 28 patients administered cetirizine, a new drug displaying a potent and selective H1 antagonism and inhibiting effect on infiltrating cells." | 5.06 | Protective effect of cetirizine in patients suffering from pollen asthma. ( Arendt, C; Bruttmann, G; Pedrali, P; Rihoux, JP, 1990) |
| "The protective efficacy of oral cetirizine, a selective and potent H1-receptor antagonist, against the immediate bronchoconstrictive response to allergen inhalation and exercise challenge was evaluated in 16 subjects with stable, predominantly mild asthma." | 5.06 | Effects of oral cetirizine, a selective H1 antagonist, on allergen- and exercise-induced bronchoconstriction in subjects with asthma. ( Dauphinee, B; Djahed, B; Gong, H; Tashkin, DP; Wu, TC, 1990) |
| " To evaluate this oral drug's efficacy in treating asthma, we examined the bronchodilator effects of 5-, 10-, and 20-mg doses as well as the protective effects of these doses against histamine-provoked bronchospasm." | 5.06 | Cetirizine inhibition of histamine-induced bronchospasm. ( Brik, A; Gong, H; Tashkin, DP, 1987) |
| "It has been demonstrated that cetirizine is able to reduce ICAM-1 expression on nasal epithelial cells and conjunctival nonspecific hyperreactivity in asthmatic asymptomatic children with MPI." | 4.80 | Minimal persistent inflammation may be controlled by cetirizine. ( Canonica, GW; Ciprandi, G, 1999) |
| "Antihistamines were investigated for use in asthma shortly after discovery over fifty years ago." | 4.79 | Antihistamines in the treatment of asthma. ( Grant, JA; Malick, A, 1997) |
| "Because the older antihistamines possessed relatively weak antihistaminic action, as well as sedative and anticholinergic effects, they could not be administered in doses high enough to confer relief to atopic patients with asthma." | 4.78 | Antihistamines in the treatment of clinical asthma. ( Rafferty, P, 1990) |
| "Objective To investigate the effects of cetirizine on Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway and mast cell activation in asthmatic mice by establishing a mouse model of asthma." | 4.12 | [Cetirizine inhibits activation of JAK2-STAT3 pathway and mast cell activation in lung tissue of asthmatic mice]. ( Huang, B; Lei, L; Luo, S; Qu, T, 2022) |
| "In cats with experimentally induced asthma, cyproheptadine and cetirizine were not effective in decreasing airway eosinophilic inflammation or in altering several other measured immunologic variables." | 3.74 | Effects of cyproheptadine and cetirizine on eosinophilic airway inflammation in cats with experimentally induced asthma. ( Jiji, RD; McGee Turner, JB; Reinero, CR; Schooley, EK; Spinka, CM, 2007) |
| "The following study was performed to further characterize a primate model of asthma using classes of drugs that target allergy (pyrilamine, cetirizine), are bronchodilators for the treatment of asthma (salbutamol, salmeterol) or are anti-inflammatory (dexamethasone)." | 3.69 | Characterization of a primate model of asthma using anti-allergy/anti-asthma agents. ( Andresen, CJ; Smith, WB; Turner, CR; Watson, JW, 1996) |
| " Safety was assessed by: reporting of adverse events, numbers of children discontinuing the study because of adverse events, height and body mass measurements, assessment of developmental milestones, and hematology and biochemistry tests." | 2.73 | Safety of levocetirizine treatment in young atopic children: An 18-month study. ( Simons, FE, 2007) |
| "Cetirizine-continuously-treated group showed a significant lower incidence of new sensitisations (p = 0." | 2.71 | Long-term cetirizine treatment may reduce new sensitisations in allergic children: a pilot study. ( Ciprandi, G; Frati, F; Marcucci, F; Milanese, M; Sensi, L; Tosca, MA, 2003) |
| "Cetirizine has several antiallergic properties that suggest a potential effect on the development of airway inflammation and asthma in infants with atopic dermatitis." | 2.69 | Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised, placebo-controlled trial: first results of ETAC. Early Treatment of the Atopic Child. ( , 1998) |
| "Cetirizine was given once a day at the dosage of 10 mg for four weeks." | 2.69 | [The efficacy of cetirizine in the treatment of mild allergic asthma due to grasses]. ( Biasi, D; Carletto, A; Corrocher, R; Pacor, ML, 1998) |
| "Cetirizine is an antiallergic drug that can reduce both inflammatory infiltrate and ICAM-I expression induced by allergen-specific conjunctival challenge." | 2.68 | Cetirizine reduces ICAM-I on epithelial cells during nasal minimal persistent inflammation in asymptomatic children with mite-allergic asthma. ( Canonica, GW; Ciprandi, G; Cozzani, S; Fasce, L; Grimaldi, I; Pronzato, C; Tosca, MA, 1996) |
| "Cetirizine is a non-sedating H1 antihistamine which is effective in the treatment of allergic rhinitis and urticaria." | 2.68 | A comparison of the effects of oral cetirizine and inhaled beclomethasone on early and late asthmatic responses to allergen and the associated increase in airways hyperresponsiveness. ( Bentley, AM; De Vos, C; Durham, SR; Hanotte, F; Walker, S, 1996) |
| "Cetirizine is a selective H1 antagonist that inhibits the eosinophil recruitment induced by allergen in the skin." | 2.67 | Inhibitory effect of cetirizine on the bronchial eosinophil recruitment induced by allergen inhalation challenge in allergic patients with asthma. ( Chanez, P; Clauzel, AM; De Vos, C; Godard, P; Michel, FB; Rédier, H; Rifaï, N, 1992) |
| "Cetirizine is a potent, selective H1 histamine receptor antagonist." | 2.67 | Effect of oral and inhaled cetirizine in allergen induced bronchoconstriction. ( de Vos, C; Ghosh, SK; Patel, KR; Rafferty, P, 1993) |
| "Cetirizine hydrochloride is an orally-active and selective histamine (H(1))-receptor antagonist." | 2.42 | Review of cetirizine hydrochloride for the treatment of allergic disorders. ( Dinakar, C; Portnoy, JM, 2004) |
| " Two of these advantages are a rapid onset of action and a once-daily dosing regimen." | 2.38 | Cetirizine: a new, nonsedating antihistamine. ( Barnes, CL; McKenzie, CA; Poinsett-Holmes, K; Webster, KD, 1993) |
| " Results demonstrate improved activity of antihistamines by 2 phytochemicals, suggesting dosing strategies for animal trials of ASX- or GB-augmented formulations for seasonal allergic rhinitis and asthma." | 1.38 | In vitro suppression of lymphocyte activation in patients with seasonal allergic rhinitis and pollen-related asthma by cetirizine or azelastine in combination with ginkgolide B or astaxanthin. ( Abal, A; Al-Awadhi, R; Al-Sharah, S; Arifhodzic, N; Azeamouzi, C; Haines, D; Mahmoud, FF; Tosaki, A, 2012) |
| "Antihistamines have been shown to have bronchodilatory effects, effects on allergen-, exercise-, and adenosine-monophosphate-challenge testing, and also to prevent allergen-induced nonspecific airways hyperresponsiveness." | 1.33 | The role of antihistamines in asthma management. ( Wilson, AM, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (5.19) | 18.7374 |
| 1990's | 40 (51.95) | 18.2507 |
| 2000's | 28 (36.36) | 29.6817 |
| 2010's | 4 (5.19) | 24.3611 |
| 2020's | 1 (1.30) | 2.80 |
| Authors | Studies |
|---|---|
| Paris, D | 1 |
| Cottin, M | 1 |
| Demonchaux, P | 1 |
| Augert, G | 1 |
| Dupassieux, P | 1 |
| Lenoir, P | 1 |
| Peck, MJ | 1 |
| Jasserand, D | 1 |
| Qu, T | 1 |
| Huang, B | 1 |
| Lei, L | 1 |
| Luo, S | 1 |
| Kim, MK | 1 |
| Lee, SY | 2 |
| Park, HS | 1 |
| Yoon, HJ | 1 |
| Kim, SH | 1 |
| Cho, YJ | 1 |
| Yoo, KH | 1 |
| Lee, SK | 1 |
| Kim, HK | 1 |
| Park, JW | 1 |
| Park, HW | 1 |
| Chung, JH | 1 |
| Choi, BW | 1 |
| Lee, BJ | 1 |
| Chang, YS | 1 |
| Jo, EJ | 1 |
| Cho, YS | 1 |
| Jee, YK | 1 |
| Lee, JM | 1 |
| Jung, J | 1 |
| Park, CS | 1 |
| Izumi, N | 1 |
| Mizuguchi, H | 1 |
| Umehara, H | 1 |
| Ogino, S | 1 |
| Fukui, H | 1 |
| Zitnik, SE | 2 |
| Rüschendorf, F | 1 |
| Müller, S | 2 |
| Sengler, C | 2 |
| Lee, YA | 2 |
| Griffioen, RW | 2 |
| Meglio, P | 2 |
| Wahn, U | 2 |
| Witt, H | 1 |
| Nickel, R | 2 |
| Marenholz, I | 1 |
| Philip, G | 1 |
| van Adelsberg, J | 1 |
| Loeys, T | 1 |
| Liu, N | 1 |
| Wong, P | 1 |
| Lai, E | 1 |
| Dass, SB | 1 |
| Reiss, TF | 1 |
| Jerzynska, J | 1 |
| Stelmach, I | 1 |
| Grzelewski, T | 1 |
| Stelmach, W | 1 |
| Krakowiak, J | 1 |
| Marcucci, F | 2 |
| Sensi, LG | 1 |
| Abate, P | 1 |
| Allocca, G | 1 |
| Ugolini, E | 1 |
| Di Cara, G | 1 |
| Incorvaia, C | 1 |
| Mahmoud, FF | 1 |
| Haines, D | 1 |
| Al-Awadhi, R | 1 |
| Arifhodzic, N | 1 |
| Abal, A | 1 |
| Azeamouzi, C | 1 |
| Al-Sharah, S | 1 |
| Tosaki, A | 1 |
| Lee, DK | 2 |
| Bates, CE | 1 |
| Currie, GP | 1 |
| Lipworth, BJ | 5 |
| Ciprandi, G | 4 |
| Frati, F | 1 |
| Sensi, L | 1 |
| Milanese, M | 2 |
| Tosca, MA | 3 |
| Portnoy, JM | 1 |
| Dinakar, C | 1 |
| Schenone, G | 1 |
| Ricca, V | 1 |
| Magnan, A | 1 |
| Gray, RD | 1 |
| Wilson, AM | 6 |
| Robb, FM | 1 |
| Soutar, PC | 1 |
| Pasquali, M | 1 |
| Baiardini, I | 1 |
| Rogkakou, A | 1 |
| Riccio, AM | 1 |
| Gamalero, C | 1 |
| Descalzi, D | 1 |
| Folli, C | 1 |
| Passalacqua, G | 1 |
| Canonica, GW | 3 |
| Nathan, RA | 1 |
| Finn, AF | 1 |
| LaForce, C | 1 |
| Ratner, P | 1 |
| Chapman, D | 1 |
| de Guia, EC | 1 |
| Hewlett, D | 1 |
| Kramer, B | 1 |
| Barnes, ML | 1 |
| Menzies, D | 1 |
| Fardon, TC | 1 |
| Burns, P | 1 |
| Kaditis, AG | 1 |
| Winnie, G | 1 |
| Syrogiannopoulos, GA | 1 |
| Simons, FE | 1 |
| Schooley, EK | 1 |
| McGee Turner, JB | 1 |
| Jiji, RD | 1 |
| Spinka, CM | 1 |
| Reinero, CR | 1 |
| Cheria-Sammari, S | 1 |
| Aloui, R | 1 |
| Gormand, F | 1 |
| Chabannes, B | 1 |
| Gallet, H | 1 |
| Grosclaude, M | 1 |
| Melac, M | 2 |
| Rihoux, JP | 4 |
| Perrin-Fayolle, M | 2 |
| Lagarde, M | 1 |
| Spector, SL | 1 |
| Nicodemus, CF | 2 |
| Corren, J | 1 |
| Schanker, HM | 1 |
| Rachelefsky, GS | 1 |
| Katz, RM | 1 |
| Siegel, SC | 1 |
| Meltzer, EO | 2 |
| Grant, JA | 3 |
| Findlay, SR | 1 |
| Glovsky, MM | 1 |
| Grossman, J | 1 |
| Kaiser, H | 1 |
| Mitchell, DQ | 1 |
| Pearlman, D | 1 |
| Selner, J | 1 |
| de Bruin-Weller, MS | 1 |
| Rijssenbeek-Nouwens, LH | 1 |
| de Monchy, JG | 1 |
| Wasserfallen, JB | 1 |
| Leuenberger, P | 1 |
| Pécoud, A | 1 |
| Ghosh, SK | 3 |
| Rafferty, P | 3 |
| De Vos, C | 6 |
| Patel, KR | 3 |
| Walsh, GM | 1 |
| Kjellman, NI | 1 |
| Barnes, CL | 1 |
| McKenzie, CA | 1 |
| Webster, KD | 1 |
| Poinsett-Holmes, K | 1 |
| Fasce, L | 1 |
| Pronzato, C | 1 |
| Cozzani, S | 1 |
| Grimaldi, I | 1 |
| Nieman, RB | 1 |
| Aaronson, DW | 1 |
| Turner, CR | 1 |
| Andresen, CJ | 1 |
| Smith, WB | 1 |
| Watson, JW | 1 |
| Gupta, SK | 1 |
| Bentley, AM | 1 |
| Walker, S | 1 |
| Hanotte, F | 1 |
| Durham, SR | 1 |
| Malick, A | 1 |
| Yuan, Y | 1 |
| Wang, Z | 1 |
| Luo, Y | 1 |
| He, T | 1 |
| Zeng, J | 1 |
| Warner, JO | 2 |
| Pacor, ML | 1 |
| Biasi, D | 1 |
| Carletto, A | 1 |
| Corrocher, R | 1 |
| Bond, GR | 1 |
| Thompson, JD | 1 |
| Fadel, R | 1 |
| Ramboer, I | 1 |
| Chatterjee, N | 1 |
| Derde, MP | 1 |
| Knol, K | 1 |
| Orr, LC | 2 |
| Sims, EJ | 2 |
| Dempsey, OJ | 1 |
| de Longueville, M | 1 |
| Aubier, M | 1 |
| Neukirch, C | 1 |
| Peiffer, C | 1 |
| Larsen, JS | 1 |
| Coutie, WJ | 1 |
| White, PS | 1 |
| Gardiner, Q | 1 |
| Siergiejko, Z | 1 |
| Michalska, I | 1 |
| Rogalewska, A | 1 |
| Chyrek-Borowska, S | 1 |
| Rédier, H | 1 |
| Chanez, P | 1 |
| Rifaï, N | 1 |
| Clauzel, AM | 1 |
| Michel, FB | 1 |
| Godard, P | 1 |
| Townley, RG | 1 |
| McIlroy, I | 1 |
| Bernheim, J | 3 |
| Arendt, C | 2 |
| Finnerty, JP | 1 |
| Holgate, ST | 1 |
| Bruttmann, G | 1 |
| Pedrali, P | 1 |
| Gong, H | 3 |
| Tashkin, DP | 3 |
| Dauphinee, B | 2 |
| Djahed, B | 1 |
| Wu, TC | 1 |
| Dijkman, JH | 1 |
| Hekking, PR | 1 |
| Molkenboer, JF | 1 |
| Nierop, G | 1 |
| Vanderschueren, R | 1 |
| Van Ganse, EH | 1 |
| Kopferschmitt-Kubler, MC | 1 |
| Couchot, A | 1 |
| Pauli, G | 1 |
| Bousquet, J | 1 |
| Emonot, A | 1 |
| Germouty, J | 1 |
| Molina, C | 1 |
| Montané, F | 1 |
| Prud'homme, A | 1 |
| Sabbah, A | 1 |
| Taytard, A | 1 |
| Dupont, P | 1 |
| Campoli-Richards, DM | 1 |
| Buckley, MM | 1 |
| Fitton, A | 1 |
| Kurzeja, A | 1 |
| Riedelsheimer, B | 1 |
| Hulhoven, R | 1 |
| Brik, A | 2 |
| Lee, E | 1 |
| Maddox, DE | 1 |
| Reed, CE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of HCP1102 Capsule : A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Clinical Trial[NCT02552667] | Phase 3 | 228 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| A Multicenter, Randomized, Double Blind, Crossover Study Comparing the Effect of MK0524 With Placebo and Concomitant Administration of MK0524 Plus Montelukast in Adult Patients With Chronic Asthma[NCT00783601] | Phase 2 | 130 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| [NCT00533208] | Phase 2 | 766 participants (Actual) | Interventional | 2003-07-31 | Completed | ||
| The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis[NCT00119015] | Phase 4 | 102 participants (Actual) | Interventional | 2005-07-31 | Terminated (stopped due to Difficulty in recruitment) | ||
| A Placebo Controlled Trial to Evaluate The Effects of Levocetirizine on Nasal Allergen Challenge And Adenosine Monophosphate Challenge In Patients With Intermittent and Persistent Allergic Rhinitis[NCT00679250] | Phase 4 | 25 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Effectiveness of Inhaled Corticosteroids in Preschool Children Following Hospital Admission for Acute Dyspnea and Wheeze[NCT00962299] | Phase 4 | 7 participants (Actual) | Interventional | 2010-05-31 | Terminated (stopped due to recruitment was unsuccesfull, only 7 patient have been included untill 2012) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Patients recorded the severity of other symptoms, including itchy nose/eyes and post-nasal drip, twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The other symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.24 |
| Fluticasone Propionate + Placebo | -0.14 |
"Patients recorded the severity of runny nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The runny nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.52 |
| Fluticasone Propionate + Placebo | -0.29 |
"Patients recorded the severity of sneezing twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The sneezing symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.22 |
| Fluticasone Propionate + Placebo | -0.25 |
"Patients recorded the severity of stuffy nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The stuffy nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -0.41 |
| Fluticasone Propionate + Placebo | -0.47 |
"Patients recorded the severity of sneezing, runny nose, stuffy nose, and other symptoms (itchy nose/eyes and post-nasal drip) twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The TNSS was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 24.~The baseline TNSS used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Fluticasone Propionate + Montelukast | -1.66 |
| Fluticasone Propionate + Placebo | -2.21 |
18 reviews available for cetirizine and Asthma, Bronchial
| Article | Year |
|---|---|
Review of cetirizine hydrochloride for the treatment of allergic disorders.
Topics: Anti-Allergic Agents; Asthma; Cetirizine; Clinical Trials as Topic; Dermatitis, Atopic; Histamine H1 | 2004 |
Anti-inflammatory pharmacotherapy for wheezing in preschool children.
Topics: Administration, Inhalation; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Cetirizine; Chi | 2007 |
The use of anti-H1 drugs in mild asthma.
Topics: Allergens; Asthma; Bronchoconstriction; Cetirizine; Clinical Trials as Topic; Histamine H1 Antagonis | 1995 |
The anti-inflammatory effects of cetirizine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Asthma; Cetirizine; Humans | 1994 |
Is there a place for antihistamines in the treatment of perennial asthma?
Topics: Adolescent; Asthma; Cetirizine; Child; Histamine Antagonists; Humans | 1993 |
Cetirizine: a new, nonsedating antihistamine.
Topics: Asthma; Cetirizine; Humans; Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal; Urticaria | 1993 |
Antihistamines in the treatment of asthma.
Topics: Asthma; Cetirizine; Clinical Trials as Topic; Histamine; Histamine H1 Antagonists; Humans | 1997 |
The clinical efficacy of antihistamines in the upper and lower airway.
Topics: Asthma; Cetirizine; Histamine H1 Antagonists; Humans; Respiratory Tract Diseases; Rhinitis | 1997 |
Early treatment of the atopic child.
Topics: Anti-Allergic Agents; Asthma; Cetirizine; Child, Preschool; Chronic Disease; Clinical Trials as Topi | 1997 |
Minimal persistent inflammation may be controlled by cetirizine.
Topics: Animals; Anti-Allergic Agents; Asthma; Cetirizine; Child; Conjunctivitis, Allergic; Humans; Hypersen | 1999 |
Clinical use of antihistamines in infants and children at risk of asthma development.
Topics: Asthma; Cetirizine; Child, Preschool; Clinical Trials as Topic; Histamine H1 Antagonists; Humans; Hy | 2000 |
What are the candidate groups for pharmacotherapeutic intervention to prevent asthma?
Topics: Anti-Allergic Agents; Asthma; Cetirizine; Child; Clinical Trials as Topic; Cromolyn Sodium; Dermatit | 2000 |
Do antihistamines have a role in asthma therapy?
Topics: Anti-Asthmatic Agents; Asthma; Bronchi; Cetirizine; Histamine; Histamine H1 Antagonists; Humans; Hyp | 2001 |
Are antihistamines useful in managing asthma?
Topics: Acetates; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Bronchospirometry; Cetirizine; Cyclopropa | 2002 |
Antiallergic properties of the second-generation H1 antihistamines during the early and late reactions to antigen.
Topics: Antigens; Asthma; Cetirizine; Chemotaxis, Leukocyte; Cold Temperature; Forced Expiratory Volume; His | 1992 |
Cetirizine: more than an antihistamine?
Topics: Allergens; Animals; Asthma; Cetirizine; Exercise; Histamine Antagonists; Histamine H1 Antagonists; H | 1991 |
Antihistamines in the treatment of clinical asthma.
Topics: Animals; Asthma; Benzhydryl Compounds; Cetirizine; Dose-Response Relationship, Drug; Forced Expirato | 1990 |
Cetirizine. A review of its pharmacological properties and clinical potential in allergic rhinitis, pollen-induced asthma, and chronic urticaria.
Topics: Animals; Asthma; Cetirizine; Chronic Disease; Histamine H1 Antagonists; Humans; Hydroxyzine; Pollen; | 1990 |
41 trials available for cetirizine and Asthma, Bronchial
| Article | Year |
|---|---|
A Randomized, Multicenter, Double-blind, Phase III Study to Evaluate the Efficacy on Allergic Rhinitis and Safety of a Combination Therapy of Montelukast and Levocetirizine in Patients With Asthma and Allergic Rhinitis.
Topics: Acetates; Adult; Anti-Allergic Agents; Anti-Asthmatic Agents; Asthma; Cetirizine; Cyclopropanes; Dou | 2018 |
IL13 variants are associated with total serum IgE and early sensitization to food allergens in children with atopic dermatitis.
Topics: Allergens; Anti-Allergic Agents; Asthma; Cetirizine; Child, Preschool; Dermatitis, Atopic; Egg Hyper | 2009 |
Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis.
Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Anti-Asthmatic Agents; Asthma; Cetirizine; | 2009 |
Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis.
Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Anti-Asthmatic Agents; Asthma; Cetirizine; | 2009 |
Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis.
Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Anti-Asthmatic Agents; Asthma; Cetirizine; | 2009 |
Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis.
Topics: Acetates; Adolescent; Adult; Aged; Anti-Allergic Agents; Anti-Asthmatic Agents; Asthma; Cetirizine; | 2009 |
Anti-inflammatory activity and clinical efficacy of a 3-month levocetirizine therapy in mite-allergic children.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Bronchi; Bronchoconstriction; Cetirizine; Child; Double-B | 2011 |
Comparative in vivo bioactivity of modern H1-antihistamines on AMP challenge in atopic asthma.
Topics: Acetates; Adenosine Monophosphate; Adult; Aged; Asthma; Bronchial Provocation Tests; Cetirizine; Cro | 2003 |
Long-term cetirizine treatment may reduce new sensitisations in allergic children: a pilot study.
Topics: Animals; Anti-Allergic Agents; Asthma; Cetirizine; Child; Child, Preschool; Double-Blind Method; Dus | 2003 |
Antihistamines added to an antileukotriene in treating seasonal allergic rhinitis: histamine and leukotriene antagonism.
Topics: Acetates; Adolescent; Adult; Asthma; Cetirizine; Cyclopropanes; Double-Blind Method; Drug Synergism; | 2004 |
Single and short-term dosing effects of levocetirizine on adenosine monophosphate bronchoprovocation in atopic asthma.
Topics: Adenosine Monophosphate; Adult; Aged; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests | 2004 |
Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters.
Topics: Adolescent; Adult; Asthma; Cetirizine; Conjunctivitis, Allergic; Double-Blind Method; Eosinophils; F | 2006 |
Comparison of cetirizine-pseudoephedrine and placebo in patients with seasonal allergic rhinitis and concomitant mild-to-moderate asthma: randomized, double-blind study.
Topics: Adrenergic Agents; Adult; Anti-Asthmatic Agents; Asthma; Cetirizine; Drug Combinations; Ephedrine; F | 2006 |
Combined mediator blockade or topical steroid for treating the unified allergic airway.
Topics: Acetates; Administration, Topical; Adolescent; Adult; Aged; Anti-Allergic Agents; Anti-Asthmatic Age | 2007 |
Safety of levocetirizine treatment in young atopic children: An 18-month study.
Topics: Asthma; Australia; Cetirizine; Dermatitis, Atopic; Double-Blind Method; Europe; Female; Histamine H1 | 2007 |
Comparison of the bronchodilatory effects of cetirizine, albuterol, and both together versus placebo in patients with mild-to-moderate asthma.
Topics: Albuterol; Asthma; Bronchodilator Agents; Cetirizine; Cross-Over Studies; Double-Blind Method; Drug | 1995 |
Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial.
Topics: Adolescent; Adult; Albuterol; Asthma; Cetirizine; Double-Blind Method; Ephedrine; Humans; Male; Plac | 1995 |
Lack of effect of cetirizine on early and late asthmatic response after allergen challenge.
Topics: Adolescent; Adult; Allergens; Animals; Antigens, Dermatophagoides; Asthma; Blood Proteins; Bronchial | 1994 |
Effect of cetirizine, a new H1 antihistamine, on the early and late allergic reactions in a bronchial provocation test with allergen.
Topics: Adolescent; Adult; Asthma; Bronchial Provocation Tests; Cetirizine; Female; Histamine H1 Antagonists | 1993 |
Effect of cetirizine, a potent H1 antagonist, on platelet activating factor induced bronchoconstriction in asthma.
Topics: Adult; Airway Resistance; Asthma; Bronchoconstriction; Cetirizine; Double-Blind Method; Female; Hist | 1993 |
Effect of oral and inhaled cetirizine in allergen induced bronchoconstriction.
Topics: Administration, Inhalation; Administration, Oral; Adult; Allergens; Asthma; Bronchoconstriction; Cet | 1993 |
Cetirizine reduces ICAM-I on epithelial cells during nasal minimal persistent inflammation in asymptomatic children with mite-allergic asthma.
Topics: Adolescent; Allergens; Animals; Antigens, Dermatophagoides; Asthma; Cetirizine; Child; Child, Presch | 1996 |
Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma.
Topics: Adolescent; Adult; Asthma; Cetirizine; Female; Humans; Male; Medical Records; Middle Aged; Patient S | 1996 |
Reversion and antihistamines.
Topics: Anti-Asthmatic Agents; Asthma; Beclomethasone; Cetirizine; Cromolyn Sodium; Glucocorticoids; Histami | 1996 |
A comparison of the effects of oral cetirizine and inhaled beclomethasone on early and late asthmatic responses to allergen and the associated increase in airways hyperresponsiveness.
Topics: Administration, Inhalation; Administration, Oral; Adult; Allergens; Antigens, Dermatophagoides; Asth | 1996 |
[Cetirizine improves the resistance of airway and pulmonary function in patients with asthma].
Topics: Adult; Airway Resistance; Anti-Allergic Agents; Asthma; Cetirizine; Female; Humans; Male; Maximal Ex | 1996 |
Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised, placebo-controlled trial: first results of ETAC. Early Treatment of the Atopic Child.
Topics: Allergens; Animals; Anti-Allergic Agents; Asthma; Cats; Cetirizine; Child, Preschool; Dermatitis, At | 1998 |
[The efficacy of cetirizine in the treatment of mild allergic asthma due to grasses].
Topics: Adult; Allergens; Analysis of Variance; Anti-Asthmatic Agents; Asthma; Cetirizine; Drug Evaluation; | 1998 |
Cetirizine inhibits bradykinin-induced cutaneous wheal and flare in atopic and healthy subjects.
Topics: Adolescent; Adult; Asthma; Bradykinin; Cetirizine; Cross-Over Studies; Dermatitis, Allergic Contact; | 2000 |
Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Anti-Asthmatic Agents; Asthma; Bronchial | 2000 |
Effect of cetirizine on bronchial hyperresponsiveness in patients with seasonal allergic rhinitis and asthma.
Topics: Adult; Anti-Allergic Agents; Asthma; Bronchial Hyperreactivity; Bronchoconstrictor Agents; Cetirizin | 2001 |
Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis.
Topics: Acetates; Administration, Inhalation; Administration, Intranasal; Adult; Airway Resistance; Anti-All | 2001 |
A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow-up.
Topics: Adolescent; Adult; Anti-Allergic Agents; Asthma; Cetirizine; Child; Dermatitis, Atopic; Double-Blind | 2001 |
Inhibitory effect of cetirizine on the bronchial eosinophil recruitment induced by allergen inhalation challenge in allergic patients with asthma.
Topics: Administration, Inhalation; Adult; Allergens; Asthma; Bronchi; Bronchial Provocation Tests; Bronchoa | 1992 |
Effect of cetirizine on histamine- and leukotriene D4-induced bronchoconstriction in patients with atopic asthma.
Topics: Adult; Asthma; Bronchial Provocation Tests; Bronchoconstriction; Cetirizine; Double-Blind Method; Dr | 1991 |
The effect of 2 weeks treatment with cetirizine on bronchial reactivity to methacholine in asthma.
Topics: Adult; Aged; Allergens; Asthma; Cetirizine; Double-Blind Method; Female; Forced Expiratory Volume; H | 1990 |
Protective effect of cetirizine in patients suffering from pollen asthma.
Topics: Adult; Allergens; Asthma; Cetirizine; Double-Blind Method; Histamine H1 Antagonists; Humans; Hydroxy | 1990 |
Effects of oral cetirizine, a selective H1 antagonist, on allergen- and exercise-induced bronchoconstriction in subjects with asthma.
Topics: Administration, Oral; Adult; Albuterol; Allergens; Asthma; Asthma, Exercise-Induced; Bronchi; Bronch | 1990 |
Prophylactic treatment of grass pollen-induced asthma with cetirizine.
Topics: Adolescent; Adult; Aged; Asthma; Benzhydryl Compounds; Cetirizine; Child; Double-Blind Method; Femal | 1990 |
Evaluation of the effect of oral cetirizine on antigen-induced immediate asthmatic response.
Topics: Administration, Oral; Adult; Allergens; Animals; Antigens; Asthma; Bronchoconstriction; Cetirizine; | 1990 |
Double-blind multicenter study of cetirizine in grass-pollen-induced asthma.
Topics: Adolescent; Adult; Aged; Asthma; Cetirizine; Child; Dose-Response Relationship, Drug; Double-Blind M | 1990 |
Cetirizine in pollen-associated asthma.
Topics: Asthma; Cetirizine; Clinical Trials as Topic; Double-Blind Method; Histamine H2 Antagonists; Humans; | 1989 |
Effect of cetirizine, a new histamine H1 antagonist, on airway dynamics and responsiveness to inhaled histamine in mild asthma.
Topics: Administration, Inhalation; Adult; Asthma; Bronchi; Bronchial Spasm; Cetirizine; Dose-Response Relat | 1987 |
Cetirizine inhibition of histamine-induced bronchospasm.
Topics: Adult; Analysis of Variance; Asthma; Bronchial Provocation Tests; Bronchial Spasm; Bronchodilator Ag | 1987 |
18 other studies available for cetirizine and Asthma, Bronchial
| Article | Year |
|---|---|
Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application i
Topics: Animals; Asthma; Female; Guinea Pigs; Histamine Antagonists; In Vitro Techniques; Lipoxygenase Inhib | 1995 |
[Cetirizine inhibits activation of JAK2-STAT3 pathway and mast cell activation in lung tissue of asthmatic mice].
Topics: Animals; Asthma; Cetirizine; Janus Kinase 2; Lung; Mast Cells; Mice; Signal Transduction; STAT3 Tran | 2022 |
Analysis of disease-dependent sedative profiles of H(1)-antihistamines by large-scale surveillance using the visual analog scale.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asthma; Butyrophenones; Cetirizine; Child; Chlorpheniram | 2008 |
Association of Filaggrin loss-of-function-mutations with atopic dermatitis and asthma in the Early Treatment of the Atopic Child (ETAC) population.
Topics: Alleles; Allergens; Asthma; Cetirizine; Dermatitis, Atopic; Double-Blind Method; Filaggrin Proteins; | 2009 |
High exposure to passive tobacco smoking and the development of asthma in an adult patient who had never smoked.
Topics: Albuterol; Asthma; Bronchodilator Agents; Budesonide; Cetirizine; Confined Spaces; Female; Histamine | 2010 |
In vitro suppression of lymphocyte activation in patients with seasonal allergic rhinitis and pollen-related asthma by cetirizine or azelastine in combination with ginkgolide B or astaxanthin.
Topics: Adult; Anti-Allergic Agents; Antioxidants; Asthma; Biomarkers; Case-Control Studies; Cells, Cultured | 2012 |
[Respiratory allergies in the child and the adult].
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Age Factors; Aged; Allergens; Anti-Allergic Ag | 2004 |
The role of antihistamines in asthma management.
Topics: Asthma; Cetirizine; Histamine; Histamine Antagonists; Histamine H1 Antagonists; Humans; Leukotriene | 2006 |
Effects of cyproheptadine and cetirizine on eosinophilic airway inflammation in cats with experimentally induced asthma.
Topics: Animals; Asthma; Bronchoalveolar Lavage Fluid; Cat Diseases; Cats; Cetirizine; Cross-Over Studies; C | 2007 |
Leukotriene B4 production by blood neutrophils in allergic rhinitis--effects of cetirizine.
Topics: Adult; Anti-Allergic Agents; Asthma; Cetirizine; Female; Granulocyte-Macrophage Colony-Stimulating F | 1995 |
Cetirizine in patients with seasonal rhinitis and concomitant asthma.
Topics: Asthma; Cetirizine; Humans; Rhinitis, Allergic, Seasonal | 1996 |
Characterization of a primate model of asthma using anti-allergy/anti-asthma agents.
Topics: Albuterol; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents; Antigens; Asthma; Bronchoconstri | 1996 |
Olanzapine pediatric overdose.
Topics: Anti-Allergic Agents; Antipsychotic Agents; Asthma; Benzodiazepines; Cetirizine; Child; Drug Overdos | 1999 |
[Atopic dermatitis in children. Prevention can reduce the incidence of asthma].
Topics: Anti-Allergic Agents; Asthma; Cetirizine; Child; Child, Preschool; Clinical Trials as Topic; Dermati | 2000 |
[Already allergic to pollen in early childhood. Can future asthma still be prevented?].
Topics: Asthma; Cetirizine; Child; Child, Preschool; Histamine H1 Antagonists; Humans; Infant; Pollen; Rando | 2002 |
[Effect of cetirizine, selective H1 antagonist of histamine on skin and bronchial reactivity and cellular histamine release in allergic diseases].
Topics: Asthma; Bronchial Provocation Tests; Cetirizine; Chronic Disease; Histamine; Humans; Neutrophils; Rh | 1992 |
[Cetirizine in allergic symptoms. General practice relevance and a profile of effects. Resume of current studies].
Topics: Asthma; Cetirizine; Eosinophils; Histamine H1 Antagonists; Humans; Hydroxyzine; Rhinitis, Allergic, | 1990 |
Clinical pharmacodynamics of antihistamines.
Topics: Animals; Asthma; Brain; Bronchial Provocation Tests; Cetirizine; Drug Evaluation; Electroencephalogr | 1987 |